1-methylthianthrene | 129250-02-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二硫类化合物
• 英文名称: 1-methylthianthrene
• 英文别名: Methylthianthrene
• CAS: 129250-02-8
• 化学式: C₁₃H₁₀S₂
• 分子量: 230.354
• InChiKey: LEIKPMFRIYWHKW-UHFFFAOYSA-N

物化性质

• 沸点：
  350.6±32.0 °C(Predicted)
• 密度：
  1.270±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  50.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-methylthianthrene 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以54%的产率得到1-methylthianthrene 5-oxide
  参考文献：
  名称：

  Photo SN-bond cleavage and related reactions of thianthrene sulfilimine derivatives

  摘要：

  Several 1- and 2-substituted thianthrene sulfilimine derivatives were prepared and the selectivity toward oxidation and N-tosylimination under several conditions was studied. In the photolysis of trans-5-(N-p-tosyl) iminothianthrene 10-oxide (trans-10), photo isomerization to cis-10 was observed. Further, photoimino-transferreaction of sulfilimines and their 10-mono- and -dioxide derivatives to sulfides was intensively studied to make clear the ability as nitrene precursors. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2007.05.004
• 作为产物：
  描述：

  2-溴噻蒽 在 叔丁基锂 、 magnesium 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 2.0h， 生成 1-methylthianthrene
  参考文献：
  名称：

  Synthesis of 1- and 2-substituted thianthrenes

  摘要：

  噻蒽 C-1 的锂化反应可以合成各种 1-取代的噻蒽，例如噻蒽-1-基硼酸和 1-三丁基锡噻蒽，它们与芳基卤化物发生钯催化偶联反应。通过锂-卤素交换，2-溴噻蒽进入 2-取代噻蒽，然后 2-硫代噻蒽与亲电物反应，包括形成 2-硼酸和 2-三丁基锡噻蒽，并与芳基卤化物偶联。

  DOI：

  10.1039/p19960002391

文献信息

• NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE
  申请人：Okano Akihiro

  公开号：US20120157459A1

  公开（公告）日：2012-06-21

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where n is 0 to 2; p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is an aryl group which is optionally substituted with L or a heterocyclic group which is optionally substituted with L; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is O, S, —NR 7 —; and R 1 to R 7 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  提供一个以新型化合物作为活性成分的GPR40激活剂，该化合物具有GPR40激动剂作用，该化合物的盐，该盐或化合物的溶剂合物，或者类似物，尤其是胰岛素分泌促进剂以及对糖尿病、肥胖症或其他疾病的预防及/或治疗剂。[解决该问题的方法] 公式(I)的化合物：（其中n为0至2；p为0至4；j为0至3；k为0至2；环A是一个芳基团，可选择性被L取代或是一个杂环团，可选择性被L取代；环B是一个苯环、一个吡啶环或一个嘧啶环；X是O，S，—NR7—；R1至R7是特定基团），该化合物的盐，或该盐或化合物的溶剂合物。
• [EN] BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5<br/>[FR] AMINES ET ETHERS DE BIPYRIDYLE UTILISES COMME MODULATEURS DU RECEPTEUR 5 METABOTROPIQUE AU GLUTAMATE
  申请人：MERCK & CO INC

  公开号：WO2005021529A1

  公开（公告）日：2005-03-10

  The present invention is directed to novel bipyridyl amine and ether compounds such as those of Formula (I): (I) (where R?1#191, R?2#191, R?3#191, X and Y are as defined herein) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel bipyridyl amine and/or ether compounds and/or compositions containing these compounds.

  本发明涉及一种新型的双吡啶基胺和醚化合物，例如式(I)中的化合物：（I）（其中R?1#191，R?2#191，R?3#191，X和Y的定义如本文所述），这些化合物是mGluR5调节剂，可用于治疗或预防涉及mGluR5的疾病和症状，包括但不限于精神和情绪障碍，如精神分裂症、焦虑、抑郁症、双相情感障碍和恐慌，以及用于疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍，如倒班工作引起的睡眠障碍和时差反应，药物成瘾、药物滥用、戒断综合征、肥胖症和其他疾病的治疗。本发明还涉及包含这些化合物的药物组合物。本发明还提供了一种通过给予这些新型双吡啶基胺和/或醚化合物和/或含有这些化合物的组合物的有效量来治疗这些障碍和症状的方法。
• [EN] FACTOR IXA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR IXA
  申请人：MERCK SHARP & DOHME

  公开号：WO2015160636A1

  公开（公告）日：2015-10-22

  In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

  在其多种实施方式中，本发明提供了一类新型的苯甲酰胺化合物，其由式（I）表示，或者其药用可接受的盐或溶剂，或者包含一种或多种所述化合物或其药用可接受的盐或溶剂的药物组合物，并提供了使用所述化合物或其药用可接受的盐或溶剂来治疗或预防血栓、栓塞、高凝血性或纤维变化的方法。
• METHOD AND CATALYST FOR SYNTHESISING AZIRIDINE
  申请人：University of East Anglia

  公开号：US20150166478A1

  公开（公告）日：2015-06-18

  The present invention relates to methods of synthesising aziridines including isotopically labelled aziridines, said methods comprising contacting an imine or one or more precursors thereof with a diazo compound in the presence of a phosphoramide or a phosphoramide-derived catalyst. The present invention also relates to aziridines, modified aziridines and aziridine-derived compounds preparable by the aforementioned methods, and to phosphoramide or phosphoramide-derived catalysts suitable for use in such methods.

  本发明涉及合成环氧乙烷的方法，包括同位素标记的环氧乙烷，所述方法包括将亚胺或其一个或多个前体与重氮化合物在磷酰胺或磷酰胺衍生的催化剂存在下接触。本发明还涉及通过上述方法制备的环氧乙烷、改性环氧乙烷和环氧乙烷衍生化合物，以及适用于这种方法的磷酰胺或磷酰胺衍生的催化剂。
• ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME
  申请人：Samsung Display Co., Ltd.

  公开号：US20190019964A1

  公开（公告）日：2019-01-17

  An organic light-emitting device includes: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode, the organic layer including an emission layer, wherein the emission layer includes an organometallic compound of Formula 1. The organometallic compound of Formula 1 may be a phosphorescent dopant:

  一种有机发光器件包括：第一电极；第二电极；以及位于第一电极和第二电极之间的有机层，该有机层包括一个发射层，其中该发射层包括化合物Formula 1的有机金属化合物。Formula 1的有机金属化合物可能是一种磷光掺杂剂。